Lasa Supergenerics share news and announcements
NSE: LASABSE: 540702Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 19 Oct 2026. Previous close ₹5.16.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹25 Cr3,595th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 0.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Sep 2026
- −24.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Sep 2026
- −24.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day.
- 37,588
Lasa Supergenerics share news and announcements
825 announcements, routine notices left out, newest first. Page 6 of 17.
May 2023
Apr 2023
19 Apr · YEARLY CERTIFICATE FROM PRACTICING COMPANY SECRETARY UNDER REG 40(9) OF SEBI (LODR) REGULATIONS 2015.
12 Apr · Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For Year Ended 31/03/2023
Mar 2023
21 Mar · Board meeting
Meeting on 21 Mar 202321 Mar · Management
21 Mar · Board meeting
Feb 2023
14 Feb · Board meeting
6 Feb · Board meeting
Meeting on 14 Feb 2023: quarterly results
Dec 2022
24 Dec · Business
Nov 2022
28 Nov · Related Party Transaction
28 Nov · Disclosure Of Related Party Transaction Under Regulation 23(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015.
Oct 2022
18 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2022
26 Sep · Meeting
Aug 2022
29 Aug · Corporate action
Jul 2022
20 Jul · Address Change
20 Jul · Announcement under Regulation 30 (LODR)-Change in Corporate Office Address
13 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2022